Monday, January 25, 2021
Home Business Investors in This One Stock Had an Amazing Year

Investors in This One Stock Had an Amazing Year


#You have to be brave to make 2,900% in a year.

#Novavax (NASDAQ:NVAX) started off 2020 in a deep, dark hole. #That’s because 2019 was a horrible year for the company. #When the biotech reported disappointing results from its phase 3 trial for #ResVax, a vaccine for respiratory syncytial virus (RSV) in babies, the market whacked the stock. #Shares traded for pennies. #Novavax’s valuation fell so hard, the company had to do a 1-for-20 reverse split in order to keep trading on the #Nasdaq #Stock #Market. #By #Dec. 31, 2019, the stock had fallen to $4 a share.

#What a difference a year makes!

- Advertisement -

#Image source: #Getty #Images

#At the beginning of the year, #Novavax’s hopes were riding on #NanoFlu, a vaccine for influenza. #Success! #Not only did it report fantastic data from its phase 3 flu trial, but simultaneously the small biotech emerged as one of the leaders in the race to vaccinate the world against a new threat, COVID-19.

The small biotech received almost $2 billion in funding from government and nonprofit sources. #And then #Novavax reported positive data from an early trial for its COVID-19 vaccine. #This development sent shares soaring incredibly high.

NVAX Chart

NVAX data by YCharts.

#Now it’s #December 2020. #Investors are waiting on phase 3 trial results from the coronavirus vaccine. #Positive data will send #Novavax shares soaring even higher, while any bad news will crash the stock.

#And yet long-term shareholders can actually relax. #Novavax is now flush with cash, and #Food and #Drug #Administration approval for its flu vaccine is highly likely. #So investors have a nice safety net if the coronavirus vaccine disappoints, while the potential upside is incredible.

- Advertisement -





[ source link ]
https://www.fool.com/investing/2020/12/31/investors-in-this-one-stock-are-having-an-amazing/

##Investors ##Stock ##Amazing ##Year

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments